Search results for "TUMORS"

showing 10 items of 1138 documents

The ITA.LI.CA Staging System: A Novel Staging System for Hepatocellular Carcinoma

2016

Background Prognostic assessment in patients with hepatocellular carcinoma (HCC) remains controversial. Using the Italian Liver Cancer (ITA.LI.CA) database as a training set, we sought to develop and validate a new prognostic system for patients with HCC. Methods and Findings Prospective collected databases from Italy (training cohort, n = 3,628; internal validation cohort, n = 1,555) and Taiwan (external validation cohort, n = 2,651) were used to develop the ITA.LI.CA prognostic system. We first defined ITA.LI.CA stages (0, A, B1, B2, B3, C) using only tumor characteristics (largest tumor diameter, number of nodules, intra- and extrahepatic macroscopic vascular invasion, extrahepatic metas…

MaleCancer Treatmentlcsh:MedicineGastroenterologyMetastasisGeographical LocationsMathematical and Statistical Techniques0302 clinical medicineMedicine and Health SciencesEthnicitiesLiver DiseasesLiver NeoplasmsGeneral MedicinePrognosisItalian PeopleCancer treatmentOncology030220 oncology & carcinogenesisHepatocellular carcinomaPhysical SciencesFemale030211 gastroenterology & hepatologyalpha-FetoproteinsRadiologyLiver cancerStatistics (Mathematics)Research Articlemedicine.medical_specialtyCarcinoma HepatocellularAsiaSurgical and Invasive Medical ProceduresGastroenterology and HepatologyResearch and Analysis MethodsCarcinomasChild healthDigestive System Procedures03 medical and health sciencesDiagnostic MedicineInternal medicineGastrointestinal TumorsmedicineCarcinomaHumansStatistical MethodsStaging systemNeoplasm StagingTransplantationbusiness.industrylcsh:RCancers and NeoplasmsHepatocellular CarcinomaOrgan Transplantationmedicine.diseaseLiver TransplantationPeople and PlacesPopulation GroupingsNeoplasm stagingbusinessMathematicsForecastingPLoS Medicine
researchProduct

Perfusion of surgical cavity wall enhancement in early post-treatment MR imaging may stratify the time-to-progression in glioblastoma

2017

Objective To determine if perfusion in surgical cavity wall enhancement (SCWE) obtained in early post-treatment MR imaging can stratify time-to-progression (TTP) in glioblastoma. Materials and methods This study enrolled 60 glioblastoma patients with more than 5-mm-thick SCWEs as detected on contrast-enhanced MR imaging after concurrent chemoradiation therapy. Two independent readers categorized the shape and perfusion state of SCWEs as nodular or non-nodular and as having positive or negative perfusion compared with the contralateral grey matter on arterial spin labeling (ASL). The perfusion fraction on ASL within the contrast-enhancing lesion was calculated. The independent predictability…

MaleCentral Nervous Systemlcsh:MedicineContrast MediaKaplan-Meier EstimatePathology and Laboratory MedicineNervous SystemDiagnostic Radiology030218 nuclear medicine & medical imaging0302 clinical medicineFunctional Magnetic Resonance ImagingMedicine and Health SciencesBlastomasMedicinelcsh:ScienceNeurological TumorsBrain MappingMultidisciplinarymedicine.diagnostic_testBrain NeoplasmsRadiology and ImagingChemoradiotherapyCombined Modality TherapyMagnetic Resonance ImagingDacarbazinePerfusionmedicine.anatomical_structureOncologyNeurology030220 oncology & carcinogenesisDisease ProgressionFemaleAnatomymedicine.symptomPerfusionResearch Articlemedicine.drugImaging TechniquesSurgical and Invasive Medical ProceduresNeuroimagingGrey matterResearch and Analysis MethodsLesion03 medical and health sciencesSigns and SymptomsText miningDiagnostic MedicineArterial Spin LabellingImage Interpretation Computer-AssistedTemozolomideHumansAgedTemozolomideSurgical Resectionbusiness.industryProportional hazards modellcsh:RCancers and NeoplasmsBiology and Life SciencesMagnetic resonance imagingmedicine.diseaseLesionslcsh:QSpin LabelsGlioblastomabusinessNuclear medicineGlioblastoma MultiformeNeuroscienceGlioblastomaPLOS ONE
researchProduct

Evaluating the incidence of pathological complete response in current international rectal cancer practice: the barriers to widespread safe deferral …

2018

INTRODUCTION: The mainstay of management for locally advanced rectal cancer is chemoradiotherapy followed by surgical resection. Following chemoradiotherapy, a complete response may be detected clinically and radiologically (cCR) prior to surgery or pathologically after surgery (pCR). We aim to report the overall complete pathological response (pCR) rate and the reliability of detecting a cCR by conventional pre-operative imaging.METHODS: A pre-planned analysis of the European Society of Coloproctology (ESCP) 2017 audit was performed. Patients treated by elective rectal resection were included. A pCR was defined as a ypT0 N0 EMVI negative primary tumour; a partial response represented any r…

MaleColorectal cancerdeferral of surgery; neoadjuvant therapy; pathology; radiology; rectal cancer; Rectal surgery; surgical oncology; Gastroenterology0302 clinical medicineProspective StudiesProspective cohort studyComplete responseMedical Auditintegumentary systemIncidence (epidemiology)IncidenceRemission InductionGastroenterologyMiddle AgedMagnetic Resonance ImagingPeer reviewEuropeTreatment Outcomedeferral of surgeryResponse Evaluation Criteria in Solid Tumors030220 oncology & carcinogenesisPreoperative Period030211 gastroenterology & hepatologyFemaleAdultmedicine.medical_specialtyRectal surgeryNO03 medical and health sciencessurgical oncologymedicineHumansneoadjuvant therapyIntensive care medicineDeferralrectal cancerPathologicalResponse Evaluation Criteria in Solid TumorsAgedNeoplasm Stagingta3126business.industryRectal NeoplasmsReproducibility of ResultsChemoradiotherapy Adjuvantmedicine.diseaseradiologyRectal Neoplasms/diagnostic imagingpathologyNeoplasm Staging/methodsbusiness
researchProduct

The global burden of cancer attributable to risk factors, 2010–19 : A systematic analysis for the Global Burden of Disease Study 2019

2022

Background: Understanding the magnitude of cancer burden attributable to potentially modifiable risk factors is crucial for development of effective prevention and mitigation strategies. We analysed results from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 to inform cancer control planning efforts globally. Methods: The GBD 2019 comparative risk assessment framework was used to estimate cancer burden attributable to behavioural, environmental and occupational, and metabolic risk factors. A total of 82 risk-outcome pairs were included on the basis of the World Cancer Research Fund criteria. Estimated cancer deaths and disability-adjusted life-years (DALYs) in 20…

MaleDEATHSDALY cancer risk factorsMedizinsystematic analysisGlobal HealthRisk AssessmentCancer preventionGlobal Burden of DiseaseRC0254Risk-attributable cancer deathsSDG 3 - Good Health and Well-beingRA0421Risk FactorsRA0421 Public health. Hygiene. Preventive MedicineQuality-Adjusted Life YearNeoplasmscancerHumansGlobal Burden of Disease StudyUKMedicine(all)MCCRC0254 Neoplasms. Tumors. Oncology (including Cancer)Risk FactorSmokingCOVID-193rd-DASGeneral MedicineDisability-adjusted life-yearsSOCIAL DETERMINANTSRisk assessmentsrisk factorCardiovascular and Metabolic Diseases3121 General medicine internal medicine and other clinical medicineOBESITYCancer burden/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingNeoplasmFemaleLIFE-STYLEQuality-Adjusted Life YearsHEALTHRAHumanRC
researchProduct

Nonendodontic periapical lesions: a retrospective descriptive study in a Brazilian population

2021

Background Several nonendodontic diseases can occur in the periapical region, resembling endodontic inflammatory conditions. Therefore, the aim of the present study was to determine the frequency of nonendodontic periapical lesions diagnosed in a Brazilian population. Material and Methods The files of two Oral Pathology laboratories were reviewed and all cases including at least one clinical diagnosis of endodontic periapical lesions were selected for the study. After initial selection, demographic and clinical data, clinical diagnosis and final diagnosis were reviewed and tabulated. Final diagnosis included endodontic periapical lesions, and benign and malignant nonendodontic periapical le…

MaleDental practiceDelayed DiagnosisDentistryOdontogenic Tumorswhole exome sequencingAmeloblastomahspa4Oral and maxillofacial pathologyHumansMedicinesomatic mutationGeneral DentistryUNESCO:CIENCIAS MÉDICASRetrospective StudiesPosterior mandibleOral Medicine and PathologyGeneral distributionbusiness.industryResearchmedicine.diseaseOdontogenicOtorhinolaryngologyClinical diagnosisSurgeryBrazilian populationtwo-hit theoryDifferential diagnosisbusinessbrafBrazilMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Molecular Pathways Involved in Prostate Carcinogenesis: Insights from Public Microarray Datasets

2012

PLoS one 7(11), e49831 (2012). doi:10.1371/journal.pone.0049831

MaleEXPRESSIONMicroarrayMicroarraysPopulationlcsh:MedicineBiologyMETABOLISMMalignancyBioinformaticsMetastasisMolecular GeneticsProstate cancerGeneticsCancer GeneticsBiomarkers TumormedicineHumansEpithelial–mesenchymal transitioneducationProstate carcinogenesislcsh:ScienceBiologyCANCER CELLSSIGNATURESOligonucleotide Array Sequence Analysiseducation.field_of_studyMultidisciplinarySystems BiologyProstate CancerCHOLESTEROLlcsh:RComputational BiologyCancers and NeoplasmsProstatic NeoplasmsGenomicsmedicine.diseaseEPITHELIAL-MESENCHYMAL TRANSITIONGene Expression Regulation NeoplasticMODELGenitourinary Tract TumorsCell Transformation NeoplasticOncologyCancer cellBIOLOGICAL PATHWAYSMedicinelcsh:QMetabolic Networks and PathwaysResearch Article
researchProduct

Lanreotide Therapy vs Active Surveillance in MEN1-Related Pancreatic Neuroendocrine Tumors2 Centimeters.

2019

Abstract Purpose Pancreatic neuroendocrine tumors (pNETs) are frequent in multiple endocrine neoplasia type 1 (MEN1) syndrome. They are usually not surgically treated unless larger than 1 to 2 cm or a growth rate > 0.5 cm per year. Somatostatin analogues represent one of the main therapeutic options in pNETs, but they have never been prospectively investigated in MEN1-related pNETs. The aim of this study was to prospectively evaluate the effectiveness of lanreotide in patients with MEN1-related pNETs < 2 cm. Methods MEN1 patients with 1 or more pNETs < 2 cm of maximal diameter were considered. Study design was prospective observational, comparing patients treated with l…

MaleEndocrinology Diabetes and MetabolismClinical BiochemistryNeuroendocrine tumorsLanreotideBiochemistryGastroenterologychemistry.chemical_compoundEndocrinologyactive surveillance lanreotide MEN1 pancreatic neuroendocrine tumors somatostatin analoguesProspective StudiesProspective cohort studyMultiple endocrine neoplasiasomatostatin analoguesMiddle AgedPrognosisTumor BurdenNeuroendocrine TumorsSomatostatinMEN1Disease ProgressionFemalelanreotideSomatostatinAdultmedicine.medical_specialtyAntineoplastic Agentspancreatic neuroendocrine tumorPeptides CyclicYoung AdultInternal medicinemedicineMultiple Endocrine Neoplasia Type 1HumansMEN1Watchful WaitingAgedCentimeterpancreatic neuroendocrine tumorsbusiness.industryBiochemistry (medical)active surveillancemedicine.diseasePancreatic NeoplasmsEndocrinologychemistryactive surveillance; lanreotide; MEN1; pancreatic neuroendocrine tumors; somatostatin analoguesTumor progressionCase-Control StudiesbusinessFollow-Up StudiesThe Journal of clinical endocrinology and metabolism
researchProduct

Nonconventional Doses of Somatostatin Analogs in Patients With Progressing Well-Differentiated Neuroendocrine Tumor

2020

Abstract Purpose To evaluate the antiproliferative activity and safety of nonconventional high doses of somatostatin analogs (HD-SSA) in patients with well-differentiated gastroenteropancreatic (GEP) neuroendocrine tumors (NET) with radiological disease progression according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria on a previous treatment. Methods A retrospective analysis of prospectively maintained databases from 13 Italian NET-dedicated centers was performed. Main inclusion criteria were: well-differentiated G1 or G2 GEP-NET, progressive disease on a previous treatment, and subsequent treatment with HD-SSA (either by increased administered dose [dose intensity] or…

MaleEndocrinology Diabetes and MetabolismClinical BiochemistryOctreotideNeuroendocrine tumorsLanreotideBiochemistryGastroenterologychemistry.chemical_compoundEndocrinologyhigh dose80 and overMedicineProspective StudiesProspective cohort studyhigh dose; lanreotide; NET; nonconventional doses; octreotide; somatostatin analogs; Adult; Aged; Aged 80 and over; Female; Follow-Up Studies; Hormones; Humans; Liver Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Prognosis; Prospective Studies; Retrospective Studies; Somatostatin; Cell DifferentiationAged 80 and overLiver NeoplasmsCell DifferentiationMiddle Agednonconventional dosePrognosissomatostatin analogsNeuroendocrine TumorsResponse Evaluation Criteria in Solid TumorsFemalelanreotideSomatostatinmedicine.drugAdultmedicine.medical_specialtyhigh dose; lanreotide; NET; nonconventional doses; octreotide; somatostatin analogsInternal medicinenonconventional dosesHumansAdverse effectAgedRetrospective Studiesbusiness.industryBiochemistry (medical)medicine.diseaseHormonesClinical trialNETEndocrinologychemistrybusinessProgressive diseaseoctreotideFollow-Up Studies
researchProduct

Regional variations in Helicobacter pylori infection, gastric atrophy and gastric cancer risk: The ENIGMA study in Chile.

2020

International audience; Background: Regional variations in gastric cancer incidence are not explained by prevalence of Helicobacter pylori, the main cause of the disease, with several areas presenting high H. pylori prevalence but low gastric cancer incidence. The IARC worldwide H. pylori prevalence surveys (ENIGMA) aim at systematically describing age and sex-specific prevalence of H. pylori infection around the world and generating hypotheses to explain regional variations in gastric cancer risk.Methods: We selected age- and sex-stratified population samples in two areas with different gastric cancer incidence and mortality in Chile: Antofagasta (lower rate) and Valdivia (higher rate). Pa…

MaleEpidemiologyPathology and Laboratory MedicineGastroenterologyGeographical locations0302 clinical medicineRisk FactorsHelicobacterEpidemiology of cancerPrevalenceMedicine and Health SciencesMedicineChileEnzyme-Linked ImmunoassaysYoung adultChildeducation.field_of_studyMultidisciplinary[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologybiologyCancer Risk FactorsStomachQRMiddle AgedBacterial Pathogens3. Good healthOncologyMedical MicrobiologyChild Preschool030220 oncology & carcinogenesisMedicineFemale030211 gastroenterology & hepatologyPathogensCancer EpidemiologyResearch ArticleAdultmedicine.medical_specialtyAdolescentSciencePopulationResearch and Analysis MethodsMicrobiologyHelicobacter InfectionsYoung Adult03 medical and health sciencesSigns and SymptomsAtrophyStomach NeoplasmsInternal medicineGastrointestinal TumorsHumansCagASeroprevalenceImmunoassayseducationMicrobial PathogensAgedChile (Country)Bacteriabusiness.industryOrganismsInfantBiology and Life SciencesCancers and NeoplasmsCancerSouth AmericaHelicobacter pylorimedicine.diseasebiology.organism_classificationHelicobacter Pyloridigestive system diseasesGastric CancerAge GroupsMedical Risk FactorsPeople and PlacesImmunologic TechniquesPopulation GroupingsClinical MedicineAtrophybusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyPLoS ONE
researchProduct

Survival of European patients diagnosed with lymphoid neoplasms in 2000-2002: results of the HAEMACARE project.

2011

The European Cancer Registry-based project on hematologic malignancies (HAEMACARE), set up to improve the availability and standardization of data on hematologic malignancies in Europe, used the European Cancer Registry-based project on survival and care of cancer patients (EUROCARE-4) database to produce a new grouping of hematologic neoplasma(defined by the International Classification of Diseases for Oncology, Third Edition and the 2001/2008 World Health Organization classifications) for epidemiological and public health purposes. We analyzed survival for lymphoid neoplasms in Europe by disease group, comparing survival between different European regions by age and sex. Design and Method…

MaleLimfomesLymphomaDiseaseLymphoid neolasmas survival0302 clinical medicineEpidemiology80 and overRegistriesChildAged 80 and overLeukemialymphoid neoplasmsIncidenceRegistries/statistics & numerical dataAge FactorsHematologyMiddle Aged3. Good healthEuropeSurvival RateChild Preschool030220 oncology & carcinogenesisFemaleLymphomasLymphoid neolasmas survival; Europe.Adultmedicine.medical_specialtyAdult; Age Factors; Aged; Aged 80 and over; Child; Child Preschool; Europe; Female; Humans; Incidence; Infant; Infant Newborn; Leukemia; Lymphoma; Male; Middle Aged; Registries; Sex Factors; Survival Analysis; Survival Rate; Young AdultNOEurope/epidemiology03 medical and health sciencesYoung AdultSex FactorsInternal medicinemedicineHumansLeukemia/classification/epidemiology/mortalityCancer survival; lymphoid neoplasmsPreschoolSurvival rateSurvival analysisddc:613AgedTumorsbusiness.industryPublic healthInfant NewbornCancerInfantLymphoma/classification/epidemiology/mortalityOriginal Articlesmedicine.diseaseNewbornSurvival AnalysisCancer survivalSurgeryCancer registrybusinessInternational Classification of Diseases for Oncology030215 immunology
researchProduct